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Pharmaceutical Process Validation is the most important 
and recognized parameters of cGMPs. The requirements of 
process validation appear of the quality system (QS) 
regulation. The goal of a quality system is to consistently 
produce products that are fit for their intended use. Process 
validation is a key element in assuring that these principles 
and goals are met. The process validation is 
standardization of the validation documents that must be 
submitted with the submission file for marketing 
authorization. The process validation is intended to assist 
manufacturers in understanding quality management 
system (QMS) requirements concerning process validation 
and has general applicability to manufacturing process. 
According to FDA, assurance of product quality is derived 
from careful and systemic attention to a number of 
importance factors, including: selection of quality process 
through in-process and end-product testing. Validation is a 
concept that has evolved inunite states in 1978.The 
concept of validation has expanded through the years to 
embrace a wide range of activities from analytical methods 
used for the quality control of drug substances and drug 
products to computerized systems for clinical trials, 
labelling or process control. Validation isfounded on, but 
not prescribed by regulatory requirements and is best 
viewed as an important and integral part of cGMP. The 
word validation simply means assessment of validity or 
action of proving effectiveness. Validation is a team effort 
where it involves people from various disciplines of the 
plant. 
WHY VALIDATION? 
● The pharmaceutical industry uses expensive material, 
sophisticated facilities and equipments and highly 
qualified personals. 
●Detailed study and controlled of the manufacturing 
process batch validation is necessary if failure cost is to be 
reduced and productivity is improved.  
● If would not be feasible to use equipment not knowing if 
it will produce the product we want, not to employ the 
people with no assurance that they can do or fail to 
implement process checks or examination to assure that 
product meet specifications. 
● The efficient use of these resources is necessary for the 
continued success of the industry. The cost of  product 
failure, rejects, reworks, recalls, complaints are the 
sufficient part of total production cost. 
●Assurance of quality, cost reduction. 
MAJOR PHASES IN VALIDATION: 
3,4
 
The activities relating to validation studies may be 
classified into three: 
Phase 1: 
This is the Pre-validation Qualification Phase which covers 
all activities relating to product research and development, 
formulation pilot batch studies, scale-up studies, transfer of 
technology to commercial scale batches, establishing 
stability conditions and storage, and handling of in-process 
and finished dosage forms, equipment qualification, 
installation qualification, master product document, 
operational qualification and process capacity. 
Phase 2: 
This is the Process Validation Phase. It is designed to 
verify that all established limits of the critical process 
parameter are valid and that satisfactory products can be 
produced even under the worst conditions. 
Phase 3: 
This is known as the Validation Maintenance Phase, it 
requires frequent review of all process related documents, 
including validation of audit reports, to assure that there 
have been no changes, deviations, failures and 
modifications to the production process and that all 
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standard operating procedures (SOPs), including change 
control procedures, have been followed. At this stage, the 
validation team comprising of individuals representing all 
major departments also assures that there have been no 
changes/deviations that should have resulted in 
requalification and revalidation3. A careful design 
andvalidation of systems and processcontrols can establish 
a high degree ofconfidence that all lots or batches 
producedwill meet their intended specifications. Itis 
assumed that throughoutmanufacturing and control, 
operationsare conducted in accordance with theprinciple of 
good manufacturing practice(GMP) both in general and in 
specificreference to sterile product manufacture. 
VALIDATION  STEPS: 
The validation steps recommended in GMP guidelines can 
be summarized as follows 3: 
●As a pre-requisite, all studies should be conducted in 
accordance with a detailed, pre-established protocol or 
series of protocols, which in turn is subject to formal –
change control procedures. 
●Both the personnel conducting the studies and those 
running the process being studied,should be appropriately 
trained and qualified and be suitable and competent to 
perform the task assigned to them. 
●All data generated during the course of studies should be 
formally reviewed and   certified as evaluated against pre-
determined criteria. 
●Suitable testing facilities,equipment,instruments and 
methodology should be available. 
●Suitable clean room facilities should be available in both 
the „local‟ and background 
environment. There should be assurance that the clean 
room environment as specified is secured through initial 
commissioning (qualification) and subsequently through 
the implementation of a programme of re-testing–
inprocess equipment should be properly installed, qualified 
and maintained. 
●When appropriate attention has been paid to the above, 
the process, if aseptic, may be validated by means of 
“process simulation” studies. 
●The process should be revalidated at intervals; and 
Comprehensive documentation should be available to 
define support and record the overall validation process. 
Planning for Validation 
All validation activities should be planned. The key 
elements of a validation programme should be clearly 
defined and documented in a validation master plan 
(VMP) or equivalent documents. 
          ●The VMP should be a summary document, which 
is brief, concise and clear. 
          ●The VMP should contain data on at least the 
following: 
1.Validation policy. 
2.Organisational structure of validation activities. 
3.Summary of facilities, systems, equipment and processes 
to be validated. 
4.Documentation format: The format to be used for 
protocols and reports. 
5.Planning and scheduling. 
6.Change control. 
7.Reference to existing document.  
8.Incase of large projects, it may be necessary to create 
separate validation master plans. 
Documentation 
A written protocol should be established that specifies how 
qualification and validation willbe conducted. The protocol 
should be reviewed and approved. The protocol should 
specify critical steps and acceptance criteria. A report that 
contain references, the qualification and/or validation 
protocol should be prepared, summarizing the results 
obtained, commenting on any deviations observed, and 
drawing the necessary conclusions, including 
recommending changes necessary to correct deficiencies. 
Any changes to the plan as defined in the protocol should 
be documented with appropriate justification. After 
completion of a satisfactory qualification, a format release 
for the next step in qualification and validation should be 
made as a written authorization. 
Validation set up 
To establish the desired attributes. These attributes include 
physical as well as chemical characteristics. In the case of 
parenterals, these desirable attributes should include 
stability, absence of pyrogens, and freedom from visible 
particles. Acceptance specifications for the   product 
should be established inorder to attain uniformity and 
consistently the desired product attributes, and the 
specifications should be derived from testing and challenge 
of the system on sound statistical basis during the initial 
development and production phases and continuing 
through subsequent routine production.The process and 
equipment should be selected to achieve the product 
specification. For example; design engineers; production 
and quality assurance people may all be involved.The 
process should be defined with a great deal of specificity 
and each step of the process should be challenged to 
determine its adequacy. These aspects are important 
inorder to assure products of uniform quality, purity and 
performance. 
PROCESS VALIDATION 
“Process Validation is establishing documented evidence 
which provides a high degree ofassurance that a specific 
process will consistently produce a product meeting its 
pre-determined specifications and quality characteristics.” 
It is beneficial to the manufacturer in many ways:14 
●It deepens the understanding of processes, decreases the 
risk, preventing problems and thus assures the smooth 
running of the process. 
●It decreases the risk of defect costs. 
●It decreases the risk of regulatory non- compliance. 
●A fully validated process may require less in-process 
controls and end- product testing. 
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Validation should thus be considered in the following 
situations: 
●Totally new process. 
●New equipment. 
● Process and equipment which have been altered to suit 
changing priorities. 
● Process where the end-product test is poor and an 
unreliable indicator of product quality. 
BASIC CONCEPT OF PROCESS VALIDATION 
●Calibration, verification and maintenance of process 
equipment. 
●requalification or revalidation. 
●Establishing specifications and performance 
characteristics. 
●election of methods, process and equipment to ensure the 
product meets specifications. 
●Qualification or validation of process and equipment. 
●Testing the final product, using validated analytical 
methods, in order to meet specifications. 
●Challenging, auditing, monitoring or sampling the 
recognised critical key steps of the process. 
Objectives of process validation 
 The manufacturing process, in addition to the 
individual equipment, must be validated. 
 The goal is to create a robust manufacturing process 
that consistently produces a drug product with 
minimal variation that adheres to quality criteria of 
purity, identity, and potency. 
 A validation plan for the manufacturing process 
should be drafted and executed by   engineers in order 
to satisfy guidelines. The validation plan usually 
involves just a PQ section. 
 Just as equipment validation, major changes after the 
initial validation will result in the need for subsequent 
revalidation. 
 In the end, process validation will ensure a robust 
product that is highly reproducible over time. 
Advantages of process validation 
 Expanded real time monitoring and adjustment of 
process. 
 Enhanced ability to statistically evaluate process 
performance and product variables. e.g., individuals; 
mean; range; control limits. 
 Enhanced data and evaluation capabilities and 
increased confidence about process reproducibility 
and product quality. 
 Improved ability to set target parameters and control 
limits for routine production, correlating with 
validation results. 
 Enhanced reporting capability. 
Reason for Process Validation 
The possible reason of performing process validation may 
include: 
 New product or existing products as per SUPAC 
changes . 
 Change in site of manufacturing. 
 Change in batch size. 
 Change in equipment. 
 Change in process existing products. 
 Change in composition or components. 
 Change in the critical control parameters. 
 Change in vendor of API or critical excipient. 
 Change in specification on input material. 
 Abnormal trends in quality parameters of product through 
review during Annual Product Review (APR). 
 Trend of Out of Specification (OOS) or Out of Trend 
(OOT) in consecutive batches. 
BASIC PRNCIPLE FOR PROCESS VALIDATION: 
[1, 
2, 5, 6, 7] 
 
The basic principle for validation may be stated as 
follows:Installation Qualification (IQ):establishing by 
objective evidence that all key aspects of the process 
equipment and ancillary system installation adhere to the 
manufacturer‟s approved specification and that the 
recommendation of the supplier of the equipment are 
suitably considered. 
IQ considerations are: 
●Equipment design features (i.e. material of construction 
cleanability, etc.) 
●Installation conditions (wiring, utility, functionality, etc.) 
●Calibration, preventative maintenance,cleaning 
schedules. 
●Safety features. 
●Supplier documentation, prints, drawings and manuals. 
●Software documented. 
●Spare parts list. 
●Environmental conditions (such as clean room 
requirements, temperature, and humidity). 
Operational Qualification (OQ):Establishing by 
objective evidence process control limits and action levels 
which result in product that all predetermined 
requirements. 
OQ considerations include: 
●Process control limits (time, temperature, pressure, line 
speed, setup conditions, etc.) 
●Software parameters. 
●Raw material specifications. 
●Process operating procedures. 
●Material handling requirements. 
●Process change control. 
●Training. 
●Short term stability and capability of the process, 
(latitude studies or control charts). 
●Potential failure modes, action levels and worst-case 
conditions. 
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●The use of statistically valid techniques such as screening 
experiments to optimize theprocess can be used during this 
phase. 
Performance Qualification (PQ): establishing by 
objective evidence that the process, under anticipated 
conditions, consistently produces a product which meets 
all predetermined requirements. 
PQ considerations include: 
● Actual product and process parameters and procedures 
established in OQ. 
● Acceptability of the product. 
● Assurance of process capability as established in OQ. 
● Process repeatability, long term process stability. 
Re–Qualification:Modification to, or relocation of 
equipment should follow satisfactory review and 
authorization of the documented change proposal through 
the change control procedure. This formal review should 
include consideration of re-qualification of the equipment. 
Minor changes or changes having no direct impact on final 
or in-process product quality should be handled through 
the documentation system ofthe preventive maintenance 
program. 
TYPES OF PROCESS VALIDATION:
1,8 
Prospective Validation:Conducted prior to the 
distribution of either a new product or a product made 
under a modified production process,where the 
modifications are significant and may affect the products 
characteristics. It is a preplanned scientific approach and 
includes the initial stages of formulation 
development,process development, setting of process 
specifications, developing in-process tests sampling plans, 
designing of batch records,defining raw material 
specifications, completion of pilot runs, transfer of 
technology from scale-up batches to commercial size 
batches, listing major process is executed and 
environmental controls.18 In Prospective Validation, the 
validation protocol is executed before the process is put 
into commercial use. It is generally considered acceptable 
that three consecutive batches/runs within the finally 
agreed parameters, giving product of the desired quality 
would constitute a proper validation of the process. It is a 
confirmation on the commercial three batches before 
marketing.[8] 
Concurrent Validation:A process where current 
production batches are used to monitor 
processing parameters. It gives of the present batch being 
studied, and offers limited assurance regarding consistency 
of quality from batch to batch.18 Concurrent Validation 
may be the practical approach under certain circumstances. 
Examples of these may be when:8 
●A previous validated process is being transferred to a 
third party contract manufacturer or to another site. 
●The product is a different strength of a previously 
validated product with the same ratio of active/inactive 
ingredients. 
●The number of lots evaluated under the Retrospective 
Validation were not sufficient to obtain a high degree of 
assurance demonstrating that the process is fully under 
control. 
●The numbers of batches produced are limited. 
●Process with low production volume per batch and 
market demand. 
●Process of manufacturing urgently needed drug due to 
shortage or absence of supply. 
●In all above cases concurrent validation is valid, provided 
following conditions are appropriately. 
●Pre-approved protocol for concurrent validation with 
rational. 
●A deviation shall be raised with justification and shall be 
approved by plant head /head process owner/Head-QMS. 
●Product behaviour and history shall be reviewed based on 
developmental/scale up /test batches. 
●A detailed procedure shall be planned for handling of the 
marketed product if any adverse reactions observed in 
concurrent validation process. 
●Concurrent validation batches shall be compiled in report 
and shall be approved all key disciplines. 
Retrospective Validation:Conducted for a product 
already being marketed, and is based on extensive data 
accumulated over several lots and over time. Retrospective 
Validation may be used for older products which were not 
validated by the fabricator at the time that they were first 
marketed, and which are now to be validated to confirm to 
the requirements of division 2, Part C of the Regulation to 
be Food and Drugs Act. Retrospective Validation is only 
acceptable for well established detailed processes and will 
be Inappropriate where there have recent changes in the 
formulation of the products, operating procedures, 
equipment and facility18 Some of the essential elements for 
Retrospective Validation are:8 
●Batches manufactured for a defined period (minimum of 
10 last consecutive batches). 
●Number of lots released per year. 
●Batch size/strength/manufacturer/year/period. 
●Master manufacturing/packaging documents. 
●List of process deviations, corrective actions and changes 
to manufacturing documents. 
●Data for stability testing for several batches. 
●Trend analysis including those for quality related 
complaints. 
Process Re-Validation:Required when there is a change 
in any of the critical process parameters, formulation, 
primary packaging components, raw material fabricator, 
major 
equipment or premises. Failure to meet product and 
process specifications in batches would also require 
process re-validation.18 
●Re-Validation becomes necessary in certain situations. 
The following are examples some of the planned or 
unplanned changes that may require re-validation: 
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●Changes in raw materials (physical properties such as 
density, viscosity, particle size distribution, and moisture, 
etc., that may affect the process or product). 
●Changes in the source of active raw material 
manufacturer. 
●Changes in packaging material (primary 
container/closure system). 
●Changes in the process (e.g., mixing time, drying 
temperatures and batch size). 
●Changes in the equipment (e.g. addition of automatic 
detection system). 
●Changes of equipment which involve the replacement of 
equipment on a “like for like” 
basis would not normally require a revalidation except that 
this new equipment. 
●Must be qualified. 
●Changes in the plant/facility. 
●Variations revealed by trend analysis (e.g. process drifts). 
STRATEGY FOR VALIDATION 
VALIDATION PROTOCOL:
5,9 
Detailed protocol for performing validations are essential 
to ensure that the process is adequately validated. Process 
validation protocols should include the following 
elements: 
●Objectives, scope of coverage of the validation study. 
●Validation team membership, their qualifications and 
responsibilities. 
●Type of validation: prospective, concurrent, 
retrospective, re-validation. 
●Number and selection of batches to be on the validation 
study. 
●A list of all equipment to be used; their normal and worst 
case operating parameters. 
●Outcome of IQ, OQ for critical equipment. 
●Requirements for calibration of all measuring devices. 
●Critical process parameters and their respective 
tolerances. 
●Process variables and attributes with probable risk and 
prevention shall be captured. 
●Description of the processing steps: copy of the master 
documents for the product. 
●Sampling points, stages of sampling, methods of 
sampling, sampling plans. 
●Statistical tools to be used in the analysis of data. 
●Training requirements for the processing operators. 
●Validated test methods to be used in inprocess testing and 
for the finished product. 
●Specifications for raw and packaging materials and test 
methods. 
●Forms and charts to be used for documenting results. 
●Format for presentation of results,documenting 
conclusions and for approval of study results. 
VALIDATION OF ANALYTICAL METHODS.
10 
Method validation confirms that the analytical procedure 
employed for a specific test is suitable for its intended use. 
The validation of an analytical method is the process by 
which it is established by laboratory studies that the 
performance characteristics of the method meet the 
requirement for the intended application. This implies that 
validity of a method can be demonstrated only though 
laboratory studies.15 
Methods should be validated or revalidated:16,17 
●before their introduction and routine use; 
● whenever the conditions change for which the method 
has been validated, e.g., instrument with different 
characteristics; and 
●wherever the method is changed and the change is 
outside the original scope of the method. 
ENVIRONMENTAL CONSIDERATIONS: 
CLEANING AND CLEAN ROOM STANDARDS 
Cleaning validation is documented proof that one can 
consistently and effectively clean a system or equipment 
items. The procedure is necessary for the following 
reasons:10,11 
●It is a customer requirement – it ensures the safety and 
purity of the product; 
●It is a regulatory requirement in active pharmaceutical 
product manufacture;  
●It also assures from an internal control and compliance 
point of view the quality of the process. 
INSPECTION OF EQUIPMENTS: 
The FDA guide to inspections12 intended to cover 
equipment cleaning (chemical residues only) expects firms 
to have written procedure (SOPs) detailing the cleaning 
processes and also written general procedure on how 
cleaning processes will be validated. 
●A standard operating procedure (SOP) for cleaning with 
a checklist; 
●A procedure for determining cleanliness (rinse or swab); 
●An assay for testing residual drug levels; 
●Pre-set criteria for testing chemical and microbial limit to 
which to equipment must be cleaned;  
●Protocol for cleaning validation. 
 
The cleaning protocol must be thorough and must be 
checked. Training is essential. A validation program 
requires 
●criteria for acceptance after cleaning, 
●appropriate methods of sampling 
●a maximum limit set for residues, and 
●test methods that must themselves be tested. 
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EXPERT EVALUATION 
This is an evaluation of the entire study against the 
protocol requirements as outlined above. It should be 
prepared and the conclusion drawn at each stage stated. 
The final conclusions should reflect whether the protocol 
requirements were met. The evaluation should include an 
assessment of the planned calibration and maintenance 
programmes for the equipment and instrumentation to 
maintain the validated conditions. In addition, all process 
monitoring and control procedures required to routinely 
ensure that the validated conditions are maintained should 
be reported. The evaluation should be signed by authorized 
officers of the organization who were members of the team 
establishing the protocol and who are appropriate expertise 
in the area assigned to them. Overall approval of the study 
should be authorized by the head of the validation team 
and the head of the quality control department.13 
THE VALIDATION REPORT 
A written report should be available after completion of 
the validation. If found acceptable, it should be approved 
and authorized (signed and dated). The report should 
include at least the following:19 
●Title and objective of study; 
●Reference to protocol; 
●Details of material; 
●Equipment; 
●Programmes and cycles used; 
●Details of procedures and test methods; 
●Results (compared with acceptance criteria); and 
●Recommendations on the limit and criteria to be applied 
on future basis. 
CONCLUSION 
From the study it can be stated that pharmaceutical Process 
Validation is the most important and recognized 
parameters of cGMP. The cGMP regulation require that 
manufacturing processes be designed and controlled to 
assure that in-process materials and finished productmeet 
predetermined quality requirements and do so consistently 
and reliably. The productshould be designed robustly 
enough to withstand variations in the manufacturing 
process and the manufacturing process should be capable 
and stable to assure continued safe products thatperform 
adequately. Process validation involves a series of 
activities taking place over thelifecycle of the product and 
process.
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